… PURPOSE: To provide a status report on the use of interferon (IFN)-a in patients with chronic
myelogenous leukemia (CML). DATA SOURCES: Data on IFN-a therapy for CML collected …

… Treatment for chronic myeloid leukemia (CML) has evolved from chemotherapy (busulfan,
hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such as imatinib. …

… with chronic myelogenous leukemia [7]. Investigations of interferon-α therapy in chronic
myelogenous leukemia … Interferon-α therapy produces hematologic responses in 60% to 80% of …

… Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of
chronic myeloid leukemia (CML) with interferon-α (IFN-α), but CCgRs are rare. The mean CCgR …

… as an investigational therapy for chronic myeloid leukemia (CML), interferon-α (IFN-α)
produced encouraging results and became one of the standards of care for chronic-phase CML, …

… that recombinant interferon-α (rIFN-α) can induce hematologic remissions and cytogenetic
improvement in newly diagnosed Philadelphia (Ph)-positive chronic myelogenous leukemia (…

… IFN-α, the molecule used in the treatment of chronic myelogenous leukemia (CML) and …
Long-term follow-up of the Italian trial of interferon-α versus conventional chemotherapy in …

… Therapies currently available for chronic myelogenous leukemia in the chronic phase (CML…
In the present study, we asseSSed the effects of TEN—o as the sole therapeutic intervention …

… The prognosis for patients with chronic myelogenous leukemia (CML) has changed
markedly since 1856, when the use of arsenicals (Fowler's solution) was first advocated in this …

… INTERFERON-α (IFN-α) was reported to be active in the treatment of chronic myeloid leukemia
(CML) in 1983 1 and to induce cytogenetic remissions in 1986.2 In 1986 we enrolled 322 …